IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced its latest automation and connectivity solution, UniView: 60™. UniView: 60 uses the Masimo Hospital Automation™ platform to aggregate and display pertinent patient information on a digital display just outside each patient’s room, allowing clinicians to familiarize themselves with the most relevant details of each patient’s case at the door in 60 seconds or less before they see the patient.
UniView: 60 is intended to improve clinical workflows by helping increase clinicians' awareness of important patient information and advisories – for example, a patient’s risk of falling, environmental warnings, lab results, prescription history, radiological images, monitoring data, and much more – optimally displayed, based on hospital preferences, to help clinicians quickly interpret pertinent information. Unlike paper records and notes, which may display outdated or incorrect information, UniView: 60 utilizes its connections to various hospital information systems to display the most appropriate, up-to-date information directly outside the patient’s room in order to increase clinical efficiency and improve hand-off communication between staff.
The hand-off communication process represents an opportunity for significant improvements in patient safety. When clinical information is absent, incomplete, erroneous, or delayed, it can lead to serious patient harm, including medication errors, inaccurate patient plans, delays in transfer to critical care, delays in discharge, and repetitive testing.1 Adopting a clear and consistent communication strategy, as leading institutions like the University of California, Irvine (UCI) Medical Center have done, has been shown to reduce ineffective hand-offs by nearly 60%.2 UniView: 60 is designed to be part of just such a strategy to improve patient safety: by incorporating patient monitoring data and other data and advisories in a standardized fashion from each patient’s full EMR history, UniView: 60 can help to make the hand-off process more consistent and effective.
UniView: 60 is one of many innovations that Masimo is developing to take advantage of the powerful connectivity and data handling architecture of the Masimo Hospital Automation platform, which connects systems across the continuum of care, from bedside monitors and connected third-party devices to electronic medical records (EMRs). Powered by ACE™, advanced translation capabilities, and a robust automation engine, the Masimo Hospital Automation platform helps to ensure interoperability and the free, secure movement of data throughout hospital systems. UniView: 60 takes advantage of this flow of data by optimizing the presentation of pertinent information about each patient’s case on an easy-to-interpret, customizable display.
As part of its vision of the hospital of the future and to further its longstanding commitment to patient safety, UCI Medical Center has chosen to deploy UniView: 60 in its new acute care unit. The new unit features the Masimo Root® Patient Monitoring and Connectivity Platform with Radius-7® wearable Pulse CO-Oximeters® at every bedside, Patient SafetyNet™ for supplemental remote monitoring and clinician notification – and at the entrance to each room, UniView: 60 digital chart displays.
“When UCI Health planned its new acute care unit at UCI Medical Center, we wanted a system that allows the entire care team to quickly see and understand a patient’s most critical information in a way that enhances patient safety and their relationship with the patient as an individual,” said UCI Health CEO Chad T. Lefteris. “Today’s clinical environment generates so much data that physicians, nurses, therapists, and other staff can lose sight of the patient. Masimo’s Hospital Automation platform and UniView: 60 meet our objectives by providing the comprehensive solution UCI Health needed to give our patients the best experience possible, while reinforcing our commitment to improving patient outcomes and safety.”
Joe Kiani, Founder and CEO of Masimo, said, “We’re delighted to announce UniView: 60 and be able to deploy it at one of our excellent local institutions, the University of California Irvine Medical Center. We’re proud to have been able to help UCI as they seek to build the hospital of the future. With UniView: 60, their clinicians are experiencing the power of the Masimo Hospital Automation platform, which connects data and automates processes throughout the hospital, and which is now being harnessed to help ensure that patients get the right care.”
@MasimoInnovates | #Masimo
Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.3 Masimo SET® has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,4 improve CCHD screening in newborns,5 and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.6-8 Masimo SET® is estimated to be used on more than 200 million patients in leading hospitals and other healthcare settings around the world,9 and is the primary pulse oximetry at 9 of the top 10 hospitals according to the 2019-20 U.S. News and World Report Best Hospitals Honor Roll.10 Masimo continues to refine SET® and in 2018, announced that SpO2 accuracy on RD SET® sensors during conditions of motion has been significantly improved, providing clinicians with even greater confidence that the SpO2 values they rely on accurately reflect a patient’s physiological status. In 2005, Masimo introduced rainbow® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve Index (ORi™). In 2013, Masimo introduced the Root® Patient Monitoring and Connectivity Platform, built from the ground up to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine® Brain Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography with NomoLine® sampling lines. Masimo’s family of continuous and spot-check monitoring Pulse CO-Oximeters® includes devices designed for use in a variety of clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7® and Radius PPG™, portable devices like Rad-67™, fingertip pulse oximeters like MightySat® Rx, and devices available for use both in the hospital and at home, such as Rad-97®. Masimo hospital automation and connectivity solutions are centered around the Masimo Hospital Automation™ platform, and include Iris Gateway®, Patient SafetyNet, Replica™, Halo ION™, UniView™, UniView: 60™, and Masimo SafetyNet™. Additional information about Masimo and its products may be found at www.masimo.com. Published clinical studies on Masimo products can be found at www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
- Flemming D and Hübner U. How to Improve Change of Shift Handovers and Collaborative Grounding and What Role Does the Electronic Patient Record System Play? Results of a Systematic Literature Review. Int J Med Inform. 2013 Jul;82(7):580-92.
- Benjamin M, Hargrave S, and Nether K. Using the Target Solution Tool to Improve Emergency Department Handoffs in a Community Hospital. Jt Comm J Qual Patient Saf. 2016 Mar;42(3):107-18.
- Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
- Taenzer AH et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
- Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
- McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
- Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
- de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
- Estimate: Masimo data on file.
About UCI Medical Center
UCI Health comprises the clinical enterprise of the University of California, Irvine. Patients can access UCI Health at primary and specialty care offices across Orange County and at its main campus, UCI Medical Center in Orange, California. The 418-bed acute care hospital provides tertiary and quaternary care, ambulatory and specialty medical clinics, and behavioral health and rehabilitation services. UCI Medical Center features Orange County’s only National Cancer Institute-designated comprehensive cancer center, high-risk perinatal/neonatal program and American College of Surgeons-verified Level I adult and Level II pediatric trauma center and regional burn center. It is the primary teaching hospital for the UCI School of Medicine. UCI Health serves a region of nearly 4 million people in Orange County, western Riverside County and southeast Los Angeles County. Follow us on Facebook and Twitter.
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo UniView: 60™ and Hospital Automation™. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including Masimo UniView: 60 and Hospital Automation, contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions and unique advantages; risks related to COVID-19; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.